Abstract
Elevated serum phosphorus and calcium are associated with arterial calcification and mortality in dialysis patients. Unlike calcium-based binders, sevelamer attenuates arterial calcification but it is unknown whether sevelamer affects mortality or morbidity. In a multicenter, randomized, open-label, parallel design trial we compared sevelamer and calcium-based binders on all-cause and cause-specific mortality (cardiovascular, infection, and other) in prevalent hemodialysis patients. A total of 2103 patients were initially randomized to treatment and 1068 patients completed the study. All-cause mortality rates and cause-specific mortality rates were not significantly different. There was a significant age interaction on the treatment effect. Only in patients over 65 years of age was there a significant effect of sevelamer in lowering the mortality rate. There was a suggestion that sevelamer was associated with lower overall, but not cardiovascular-linked, mortality in older patients. We suggest that further research is needed to confirm these findings.
Original language | English (US) |
---|---|
Pages (from-to) | 1130-1137 |
Number of pages | 8 |
Journal | Kidney international |
Volume | 72 |
Issue number | 9 |
DOIs | |
State | Published - Nov 2007 |
Keywords
- Calcium
- Hemodialysis
- Mortality
- Phosphate-binders
- Phosphorus
- Sevelamer
ASJC Scopus subject areas
- Nephrology